XXIV - Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
Delayed ILD, -pneumonitis, -fibrosis
Last update 11/09/2026
May occur weeks to years after termination of treatment with the drug or exposure to the agent
XXIV - Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
Last update 11/09/2026
May occur weeks to years after termination of treatment with the drug or exposure to the agent
Frequency - Incidence
Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic